Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation
Article first published online: 23 MAR 2010
©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 10, Issue 8, pages 1823–1833, August 2010
How to Cite
Degertekin, B., Han, S.-H. B., Keeffe, E. B., Schiff, E. R., Luketic, V. A., Brown, Jr., R. S., Emre, S., Soldevila-Pico, C., Reddy, K. R., Ishitani, M. B., Tran, T. T., Pruett, T. L., Lok, A. S. F. and the NIH HBV-OLT Study Group (2010), Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation. American Journal of Transplantation, 10: 1823–1833. doi: 10.1111/j.1600-6143.2010.03046.x
- Issue published online: 23 JUL 2010
- Article first published online: 23 MAR 2010
- Received 07 October 2009, revised 30 November 2009 and accepted for publication 21 December 2009
- 6Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006; 12: 124–133., , et al.
- 19Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182–187., , et al.
- 20An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741–748., , et al.